Catalent Expands Singapore Clinical Trials Hub
Catalent plans a $4.6 million investment to expand secondary packaging and storage in Asia.
Catalent Pharma Solutions announced on Feb. 2, 2016 an investment of $4.6 million to expand its Singapore clinical supply facility by building GMP space for secondary packaging. The investment will double the ambient storage space and quadruple cold storage capacity, the company reports.
Established in 1998, Catalent’s Singapore site provides clinical supply services including project and supply chain management, comparator sourcing, clinical label printing, secondary packaging, clinical storage, import/export management, importer of record service, and returns and destruction management services. It has served as a key regional hub for studies in Australia, Singapore, Korea, Hong Kong and other countries in Southeast Asia.
Source: Catalent Pharma Solutions
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
